Recombinant TFPI and variants:potential implications in the treatment of cardiovascular disorders

Bibliography

• WACHTFOGEL YT, DELA CADENA RA, COLMAN RW: Structural biology, cellular interactions and patho-physiology of the contact system. Thromb. Res. (1993) 72 (1):1–21.
   PubMed Web of Science ®Google Scholar
• COLMAN RW, SCHMAIER AH: Contact system: a vascular biology modulator with anticoagulant, profibrino-lytic, antiadhesive, and proinflammatory attributes. Blood (1997) 90(10):3819–3843.
   PubMed Web of Science ®Google Scholar
• BROZE GJ JR: Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coag. Fibri-nol. (1995) 6\(Suppl. 1):S7–S13.
   Google Scholar
• BROZE GJ JR: The role of tissue factor pathway inhibi-tor in a revised coagulation cascade. Semin. Hematol. (1992) 29(3):159–169.
   PubMed Web of Science ®Google Scholar
• BROZE GJ JR: Tissue factor pathway inhibitor and the revised theory of coagulation. Annu. Rev. Med. (1995) 46:103–112.
   PubMed Web of Science ®Google Scholar
• MANN KG, KALAFATIS M: The coagulation explosion. Cerebrovasc. Dis. (1995) 5:93–97.
   Web of Science ®Google Scholar
• CAMERER E, KOLSTO AB, PRYDZ H: Cell biology of tis-sue factor, the principal initiator of blood coagulation. Thromb. Res. (1996) 81(0:1–41.
   PubMed Web of Science ®Google Scholar
• OSTERUD B: Cellular interactions in tissue factor ex-pression by blood monocytes. Blood Coag. Fibrinol. (1995) 6\(Suppl. 1):S20–S25.
   Google Scholar
• MORISSEY JH: Tissue factor interactions with factor VII: measurement and clinical significance of factor VIIa in plasma. Blood Coag. Fibrinol. (1995) 6\(Suppl. 1):S14–S19.
   Google Scholar
• WADA H, WAKITA Y, SHIKU H: Tissue factor expression in endothelial cells in health and disease. Blood Coag. Fibrinol. (1995) 6\(Suppl. 1):S26–S31.
   Google Scholar
• FRANCIS JL, CARVALHO M, FRANCIS DA: The clinical value of tissue factor assays. Blood Coag. Fibrinol (1995) 6\(Suppl. 1):S37–S44.
   Google Scholar
• TAUBMAN MB, FALLON JT, SCHECTER AD et al.: Tissue factor in the pathogenesis of atherosclerosis. Thromb. Haemost. (1997) 78(1):200–204.
   PubMed Web of Science ®Google Scholar
• CAMERER E, KOLSTO AB, PRYDZ H: Cell biology of tis-sue factor. Thromb. Res. (1996) 81(1):1–41.
   PubMed Web of Science ®Google Scholar
• OSTERUD B: Tissue factor: a complex biological role. Thromb. Haemost. (1997) 78(1)755–758.
   Google Scholar
• ROSENBERG RD, ROSENBERG JS: Natural anticoagulant mechanisms.j Clin. Invest. (1984) 74(0:1–6.
   Google Scholar
• TOLLEFSEN DM: Insight into the mechanism of action of heparin cofactor II. Thromb. Haemost. (1995) 74(5):1209–1214.
   PubMed Web of Science ®Google Scholar
• DAHLBACK B: The protein C anticoagulant system: in-herited defects as basis for venous thrombosis. Thromb. Res. (1995) 77(0:1–43.
   PubMed Web of Science ®Google Scholar
• BROZE GJ Jr, GIRARD TJ, NOVOTNY WF: Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry (1990) 29(33):7539–7546.
   PubMed Web of Science ®Google Scholar
• BROZE GJ Jr: Tissue factor pathway inhibitor. Thromb. Haemost. (1995) 74(1):90–93.
   PubMed Web of Science ®Google Scholar
• GIRARD TJ, WARREN LA, NOVOTNY WF et al.: Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature (1989) 338(6215):518–520.
   PubMed Web of Science ®Google Scholar
• GIRARD TJ, MCCOURT D, NOVOTNY WG: Endogenous phosphorylation of the lipoprotein-associated coagu-lation inhibitor at serine-2. Biochem. J. (1990) 270(3):621–625.
   PubMed Web of Science ®Google Scholar
• BROZE GJ JR, WARREN LA, NOVOTNY WF et al.: The lipoprotein-associated coagulation inhibitor that in-hibits the factor VII-tissue factor complex also inhibits factor Xa: insights into its possible mechanism of ac-tion. Blood (1988) 71(2)335–343.
   Google Scholar
• HUANG ZF, WUN TC, BROZE GJ JR: Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J. Biol. Chem. (1993) 286(36):26950–26955.
   Google Scholar
• LINDHOUT T, FRANSSEN J, WILLEMS G: Kinetics of the inhibition of tissue factor-factor VIIa by tissue factor pathway inhibitor. Thromb. Haemost. (1995) 74(3)910–915.
   Google Scholar
• LINDHOUT T, WILLEMS G, BLEZER R, HEMKER HC: Kinet-ics of the inhibition of human factor Xa by full-length and truncated recombinant tissue factor pathway in-hibitor. Biochem. J. (1994) 297:131–136.
   PubMed Web of Science ®Google Scholar
• LINDHOUT T, SALEMINK I, VALENTIN S, WILLEMS GM:Tissue factor pathway inhibitor: regulation of its in-hibitory activity by phospholipid surfaces. Haemostasis (1996) 26\(Suppl. 4):89–97.
   Google Scholar
• RAPAPORT SI: Inhibition of factor VIIa/tissue factor-induced blood coagulation: with particular emphasis upon a factor Xa-dependent inhibitory mechanism. Blood (1989) 73(2):359–365.
   PubMed Web of Science ®Google Scholar
• WARN-CRAMER BJ, RAO LVM, MAKI SL, RAPAPORT SI: Modifications of extrinsic pathway inhibitor (EPO and factor Xa that affect their ability to interact and to in-hibit factor VIIa/tissue factor: evidence for a two-step model of inhibition. Thromb. Haemost. (1988) 60(3) :453–456.
   PubMed Web of Science ®Google Scholar
• RAPAPORT SI: The extrinsic pathway inhibitor: a regu-lator of tissue factor-dependent blood coagulation. Thromb. Haemost. (1991) 66(1):6–15.
   PubMed Web of Science ®Google Scholar
• YONEDA T, KOMOOKA H, UMEYAMA H: A computer modeling study of the interaction between tissue fac-tor pathway inhibitor and blood coagulation factor Xa. J. Protein. Chem. (1997) 16(6):597–605.
   PubMedGoogle Scholar
• PETERSEN LC, BJORN SE, OLSEN OH et al.: Inhibitory properties of separate recombinant Kunitz-type-protease inhibitor domains from tissue-factor-pathway inhibitor. Eur. J. Biochem. (1996) 235 (1-2) 310–316.
   PubMedGoogle Scholar
• NORDFANG 0, BJORN SE, VALENTIN S et al.: The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity. Biochemistry (1991) 30(43):10371–10376.
   Google Scholar
• VALENTIN S, NORDFANG 0, BREGENGARD C, WILDGOOSE P: Evidence that the C-terminus of tissue factor pathway inhibitor (TM is essential for its in vi-tro and in vivo interaction with lipoproteins. Blood Coag. Fibrinol. (1993) 4(5):713–720.
   PubMed Web of Science ®Google Scholar
• BAJAJ MS, KUPPUSWAMY MN, SAITO H, SPITZER SG, BA-JAJ SP: Cultured normal human hepatocytes do not © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(7) synthesise lipoprotein-associated coagulation inhibi-tor: evidence that the endothelium is the principal site of synthesis. Proc. Natl. Acad. Sci. (1990) 87(22):8869–8873.
   Google Scholar
• PETERSEN LC, VALENTIN S, HEDNER U: Regulation of theextrinsic pathway system in health and disease: the role of factor Vila and tissue factor pathway inhibitor. Thromb. Res. (1995) 79(0:1–47.
   PubMed Web of Science ®Google Scholar
• NOVOTNY WF, GIRARD TJ, MILETICH JP, BROZE GJ Jr: Pu-rification and characterisation of lipoprotein associ-ated coagulation inhibitor from human plasma. J. Biol. Chem. (1989) 264(30:18832–18837.
   PubMed Web of Science ®Google Scholar
• BROZE GJ Jr, LANGE GW, DUFFIN KL, MACPHAIL L: Het-erogeneity of plasma tissue factor pathway inhibitor. Blood Coag. Fibrinol (1994) 5(4):551–559.
   PubMed Web of Science ®Google Scholar
• GIRARD TJ: Tissue factor pathway inhibitor. In: New Therapeutic Agents in Thrombosis and Thrombolysis. Sasa-hara AA, Loscalzo J (Eds.), Marcel Dekker, Inc., New York, Basel. (1997)225–260.
   Google Scholar
• NOVOTNY WF, GIRARD TG, MILETICH JP, BROZE GJ Jr: Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood (1988) 72(6)2020–2025.
   Google Scholar
• HOPPENSTEADT DA: Tissue factor pathway inhibitor as a modulator of post surgical thrombogenesis. Experi-mental and clinical studies. Thesis for the degree of Doc-tor of Philosophy, University of London (1996).
   Google Scholar
• KAISER B, FAREED J: Recombinant full-length tissue fac-tor pathway inhibitor (TFPI) prevents thrombus for-mation and re-thrombosis after lysis in a rabbit model of jugular vein thrombosis. Thromb. HaemosL (1996) 76(4):615–620.
   PubMed Web of Science ®Google Scholar
• KAISER B; HOPPENSTEADT DA, JESKE W, WUN TC, FAREED J: Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro - modulatory action of glycosaminoglycans. Thromb. Res. (1994) 75(6)609–616.
   Google Scholar
• KAISER B, JESKE W, HOPPENSTEADT D, FAREED J: In-hibitory effects of TFPI variants on thrombin and fac-tor Xa generation in fibrinogen-deficient human plasma. Thromb. Res. (1994) 76 (6) :561–568.
   PubMed Web of Science ®Google Scholar
• KAISER B, HOPPENSTEADT D, FAREED J: Effect of acti-vated protein C (APC) and tissue factor pathway in-hibitor (TFPI) on thrombin and factor Xa generation in fibrinogen-deficient human plasma. Thromb. Hae-most. (1997) (Suppl.):415.
   Google Scholar
• VALENTIN S, OSTERGAARD P, KRISTENSEN H, NORD-FANG 0: Synergism between full length TFPI and hepa-rin: evidence for TFPI as an important factor for the antithrombotic activity of heparin. Blood Coag. Fibri-nol. (1992) 3(2):221–222.
   PubMed Web of Science ®Google Scholar
• ABILDGAARD U, LINDAHL AK, SANDSET PM: Heparin re-quires both antithrombin and extrinsic pathway in-hibitor for its anticoagulant effect in human blood. Haemostasis (1991) 21 (4):254–257.
   PubMedGoogle Scholar
• WUN TC: Lipoprotein-associated coagulation inhibitor (LAC° is a cofactor for heparin: synergistic anticoagulant action between LACI and sulfated polysaccharides. Blood (1992) 79(2)430–438.
   Google Scholar
• LINDAHL AK, ABILDGAARD U, STAALESEN R: The antico-agulant effect in heparinized blood and plasma result-ing from interactions with extrinsic pathway inhibitor. Thromb. Res. (1991) 64 (2) :155–168.
   PubMed Web of Science ®Google Scholar
• VAN'T VEER C, MANN KG: Regulation of tissue factor ini-tiated thrombin generation by the stoichiometric in-hibitors tissue factor pathway inhibitor, antithrombin-III, and heparin. J. Biol. Chem. (1997) 272(7)4367–4377.
   Google Scholar
• VAN'T VEER C, GOLDEN NJ, KALAFATIS M, MANN KG: In-hibitory mechanism of the protein C pathway on tis-sue factor-induced thrombin generation. Synergistic effect in combination with tissue factor pathway in-hibitor. J. Biol. Chem. (1997) 272(12):7983–7984.
   Google Scholar
• KAISER B, JESKE W, WALENGA JM, FAREED J: Tissue fac-tor pathway inhibitor (TFPI) inhibits tissue factor- and factor Xa- but not _-thrombin-, TRAP- and arachidonic acid-induced platelet activation. Ann. Hematol. (1998) 76(Suppl. D:A67.
   Google Scholar
• ABENDSCHEIN DR, MENG YY, TORR-BROWN S, SOBEL BE: Maintenance of coronary patency after fibrinoly-sis with tissue factor pathway inhibitor. Circulation (1995) 92(4):944–949.
   PubMed Web of Science ®Google Scholar
• BREGENGARD C, NORDFANG 0, WILDGOOSE P et al: The effect of two-domain tissue factor pathway inhibi-tor on endotoxin-induced disseminated intravascular coagulation in rabbits. Blood Coag. Fibrinol. (1993) 4(5)699–706.
   Google Scholar
• CARR C, BILD GS, CHANG ACK et al.: Recombinant E.co/i-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon Gram-negative model of septic shock. Circ. Shock (1995) 44 (3) :126–137.
   Google Scholar
• CREASEY AA, CHANG ACK, FEIGEN L et al: Tissue factorpathway inhibitor reduces mortality from Escheri-chia coli septic shock. J. Clin. Invest. (1993) 91(6)2850–2860.
   Google Scholar
• DAY KC, HOFFMAN LC, PALMIER MO et al. Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagula-tion in the rabbit. Blood (1990) 76(8):1538–1545.
   PubMed Web of Science ®Google Scholar
• ELSAYED YA, NAKAGAWA K, KAMIKUBO Y, ENJYOJI K, KATO H, SUEISHI K: Effects of recombinant human tis-sue factor pathway inhibitor on thrombus formation and its in vivo distribution in a rat DIC model. Am. J. Clin. Pathol (1996) 106(5) :574–583.
   PubMed Web of Science ®Google Scholar
• HASKEL EJ, TORR SR, DAY KC et al.: Prevention of arte-rial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor. Circula-tion (1991) 84(2):821–827.
   PubMed Web of Science ®Google Scholar
• HOLST J, LINDBLAD B, BERGQVIST D et al.: Antithrom-botic effect of recombinant truncated tissue factor pathway inhibitor (TFPI1_161) in experimental venous thrombosis - a comparison with low molecular weight heparin. Thromb. Haemost. (1994) 71(2):214–219. z© Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(7)
   Google Scholar
• HOLST J, LINDBLAD B, WESTERLUND G et al.: Pharma-cokinetics and delayed experimental antithrombotic effect of two domain non-glycosylated tissue factor pathway inhibitor. Thromb. Res. (1996) 81(4)461–470.
   Google Scholar
• HOLST J, LINDBLAD B, NORDFANG 0, OSTERGAARD PB, HEDNER U: Does glycosylation influence the experi-mental antithrombotic effect of a two-domain tissue factor pathway inhibitor? Haemostasis (1996) 26(1)23–30.
   Google Scholar
• JANG Y, GUZMAN LA, LINCOFF AM et al.: Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral ar-tery injury model. Circulation (1995) 92(10):3041–3050.
   PubMed Web of Science ®Google Scholar
• KAMIKUBO Y, HAMURO T, MATSUDA J et al.: Antithrom-botic effect of human recombinant tissue factor path-way inhibitor on endotoxin-induced intravascular coagulation in rats: concerted effect with antithrom-bin. Thromb. HaemosL (1996) 76(4):621–626.
   PubMed Web of Science ®Google Scholar
• KHOURI RK, KOUDSI B, KAIDING F, ORNBERG RL, WUN TC: Prevention of thrombosis by topical application of tissue factor pathway inhibitor in a rabbit model of vascular trauma. Ann. Plast. Surg. (1993) 30(5)398–404.
   Google Scholar
• LANTIERI LA, OZBEK MR, DEUNE ED et al.: Prevention of microvascular thrombosis by topical application of re-combinant tissue factor pathway inhibitor. Plast. Re-constr. Surg. (1996) 97(3):587–594.
   PubMed Web of Science ®Google Scholar
• LINDAHL AK, SANDSET PM, THUNE-WIIGER M, NORD-FANG 0, SAKARIASSEN KS: Tissue factor pathway in-hibitor prevents thrombus formation on procoagulant subendothelial matrix. Blood Coag. Fibri-nol. (1994) 5(5):755–760.
   PubMed Web of Science ®Google Scholar
• SPOKAS EG, WUN TC: Venous thrombosis produced in the vena cava of rabbits by vascular damage and stasis. Pharmacol Toxicol. Methods (1992) 27(4):225–232.
   PubMed Web of Science ®Google Scholar
• VEER C, HACKENG TM, DELAHAYE C, SIXMA JJ, BOUMA BN: Activated factor X and thrombin formation trig-gered by tissue factor on endothelial cell matrix in a flow model: effect of the tissue factor pathway inhibi-tor. Blood (1994) 84(4):1132–1142.
   PubMed Web of Science ®Google Scholar
• OLTRONA L, SPEIDEL CM, RECCHIA D et al: Inhibition of tissue factor-mediated coagulation markedly attenu-ates stenosis after balloon-induced arterial injury in minipigs. Circulation (1997) 96(2)646–652.
   Google Scholar
• HOLST J, LINDBLAD B, MATTHIASSON SE et al.: Experi-mental haemorrhagic effect of two-domain non-glycosylated tissue factor pathway inhibitor com-pared to low molecular weight heparin. Thromb. Hae-most. (1996) 75(4):585–589.
   PubMed Web of Science ®Google Scholar
• LEFKOVITS J, MALYCKY JL, RAO JS et al.: Selective inhibi-tion of factor Xa is more efficient than factor VIIa-tissue factor complex blockade at facilitating coronary thrombolysis in the canine model. J. Am. Coll. Cardiol. (1996) 28(7):1858–1865.
   PubMed Web of Science ®Google Scholar
• SATO Y, ASADA Y, MARUTSUKA K, HATAKEYAMA K, KA-MIKUBO Y, SUMIYOSHI A: Tissue factor pathway inhibi-tor inhibits aortic smooth muscle cell migration induced by tissue factor/factor VIIa complex. Thromb. Haemost. (1997) 78(3):1138–1141.
   PubMed Web of Science ®Google Scholar
• KAMIKUBO Y, NAKAHARA Y, TAKEMOTO Set al: Humanrecombinant tissue factor pathway inhibitor prevents the proliferation of cultured human neonatal aortic smooth muscle cells. FEBS Lett. (1997) 407(0:116–120.
   PubMed Web of Science ®Google Scholar
• JESTY J, LORENZ A, RODRIGUEZ J, WUN TC: Initiation ofthe tissue factor pathway of coagulation in the pres-ence of heparin: control by antithrombin III and tissue factor pathway inhibitor. Blood (1996) 87(6)2301–2307.
   Google Scholar
• NOVOTNY WF, PALMIER M, WUN TC, BROZE G JR, MI-LETICH JP: Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibi-tor. Blood (1991) 78(2)394–400.
   Google Scholar
• HOPPENSTEADT DA, JESKE W, FAREED J, BERMES EW JR:The role of tissue factor pathway inhibitor in the me-diation of the antithrombotic actions of heparin and low-molecular-weight heparin. Blood Coag. Fibrinol (1995) 6\(Suppl. 1):S57–64.
   Google Scholar
• HUBBARD AR, WELLER LJ, GRAY E: Measurement of tis-sue factor pathway inhibitor in normal and post-heparin plasma. Blood Coag. Fibrinol. (1994) 5(5)819–823.
   Google Scholar
• SANDSET PM, ABILDGAARD U, LARSEN ML: Heparin in-duces release of extrinsic coagulation pathway inhibi-tor (EPI). Thromb. Res. (1988) 50(6):803–813.
   PubMed Web of Science ®Google Scholar
• SANDSET PM: Tissue factor pathway inhibitor (TFPI) - an update. Haemostasis (1996) 26 (Suppl. 4):154–165.
   Google Scholar
• LINDAHL AK, ABILDGAARD U, STAALESEN R: The antico-agulant effect in heparinized blood and plasma result-ing from interactions with extrinsic pathway inhibitor. Thromb. Res. (1991) 64 (2) :155–168.
   PubMed Web of Science ®Google Scholar
• TIEMANN C, BRINKMANN T; KLEESIEK K: Detection ofthe three Kunitz-type single domains of membrane-bound tissue factor pathway inhibitor (TFPI) by flow cytometry. Eur. J. Clin. Chem. Clin. Biochem. (1997) 35(11)855–860.
   Google Scholar
• HAMAMOTO T, KISIEL W: The effect of heparin on theregulation of factor VIIa-tissue factor activity by tissue factor pathway inhibitor. Blood Coag. Fibrinol. (1996) 7(4)470–476.
   Google Scholar
• IVERSEN N, SANDSET PM, ABILDGAARD U, TORJESEN PA:Binding of tissue factor pathway inhibitor to cultured endothelial cells - influence of glycosaminoglycans. Thromb. Res. (1996) 84(4):267–278.
   PubMed Web of Science ®Google Scholar
• KAISER B, GLUSA E, HOPPENSTEADT DA et al.: A super-sulfated low molecular weight heparin (IK-SSH) in-creases plasma levels of free and total TFPI after i.v. and s.c. administration in man. Blood Coag. Fibrinol (In Press.)
   Google Scholar
• HOPPENSTEADT DA, JESKE W, LEITZ H et al.: Heparinand LMW heparin not only release TFPI from endoge-nous vascular sites but also favor the equilibrium of free TFPI. Thromb. HaemosL (1997) (Suppl.):410.
   Google Scholar
• BICK RL, KAPLAN H: Syndromes of thrombosis and hy-percoagulability: congenital and acquired thrombo-philias. J. Appl. Thromb. Hemost. (1998) 4(0:25-50. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(7)
   Google Scholar
• HUANG ZF, HIGUCHI D, LASKY N, BROZE GJ JR: Tissue factor pathway inhibitor gene disruption produces in-trauterine lethality in mice. Blood (1997) 90(3) :944–951.
   PubMed Web of Science ®Google Scholar
• LLOBET D, FALKON L, MATEO J et al.: Low levels of tissue factor pathway inhibitor (TFP0 in two out of three members of a family with thrombophilia. Thromb. Res. (1995) 80(5):413–418.
   PubMed Web of Science ®Google Scholar
• NOVOTNY WF, BROWN SG, MILETICH JP, RADER DJ, BROZE GJ JR: Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood (1991) 78(2):387–393.
   PubMed Web of Science ®Google Scholar
• SHIMURA M, WADA H, WAKITA Y et al.: Plasma tissue factor and tissue factor pathway inhibitor levels in pa-tients with disseminated intravascular coagulation. Am. J. Hematol. (1997) 55(4):169–174.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI H, SATO N, SHIBATA A: Plasma tissue factor pathway inhibitor in disseminated intravascular co-agulation: comparison of its behavior with plasma tis-sue factor. Thromb. Res. (1995) 80(4)339–348.
   Google Scholar
• VELASCO F, LOPEZ-PEDRERA C, BORRELL M, FONTCU-BERTA J, TORRES A: Elevated levels of tissue factor path-way inhibitor in acute non-lymphoblastic leukemia patients with disseminated intravascular coagulation. Blood Coag. Fibrinol (1996) 8:70–72.
   Web of Science ®Google Scholar
• KAMIKURA Y, WADA H, YAMADA A et al.: Increased tis-sue factor pathway inhibitor in patients with acute myocardial infarction. Am. J. Hematol. (1997) 55 (4):183–187.
   PubMed Web of Science ®Google Scholar
• LORENA M, PEROLINI S, CASAZZA F, MILANI M, CIM-MINIELLO C: Fluvastatin and tissue factor pathway in-hibitor in type IIA and IIB hyperlipidemia and in acute myocardial infarction. Thromb. Res. (1997) 87(4)397–403.
   Google Scholar
• MOOR E, HAMSTEN A, KARPE F et al: Relationship of tis-sue factor pathway inhibitor activity to plasma lipo-proteins and myocardial infarction at a young age. Thromb. Haemost. (1994) 71 (6):707–712.
   PubMed Web of Science ®Google Scholar
• ABUMIYA T, YAMAGUCHI T, TERASAKI T et al.: De-creased plasma tissue factor pathway inhibitor activity in ischemic stroke patients. Thromb. Haemost. (1995) 74 (4) :1050–1054.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI M, WADA H, WAKITA Y et al.: Decreasedplasma tissue factor pathway inhibitor levels in pa-tients with thrombotic thrombocytopenic purpura. Thromb. Haemost. (1995) 73 (0 :10–14.
   PubMed Web of Science ®Google Scholar
• SABHARWAL AK, BAJAJ SP, AMERI A et al.: Tissue factor pathway inhibitor and von Willebrand factor antigen levels in adult respiratory distress syndrome and in a primate model of sepsis. Am. J. Respir. Grit. Care Med. (1995) 151:758–767.
   PubMed Web of Science ®Google Scholar
• BERETTINI M, PARISE P, RICOTTA S et al.: Increased plasma levels of tissue factor pathway inhibitor (TFP0 after n-3 polyunsaturated fatty acids supplementation in patients with chronic atherosclerotic disease. Thromb. Haemost. (1996) 75(3):395–400.
   PubMed Web of Science ®Google Scholar
• AMENGUAL 0, ATSUMI T, KHAMASHTA MA, HUGHES GRV: The role of the tissue factor pathway in the hyper-coagulable state in patients with the antiphospholipid syndrome. Thromb. Haemost. (1998) 79:276–281.
   PubMed Web of Science ®Google Scholar
• HANSEN JB, HUSEBY KR, HUSEBY NE, EZBAN M, NOR-DOY A: Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tis-sue factor-induced coagulation in vitro. Thromb. Res. (1997) 85(5):413–425.
   PubMed Web of Science ®Google Scholar
• LINDAHL AK: Tissue factor pathway inhibitor in health and disease. Trends Cardiovasc. Med. (1995) 5 (4) :167–171.
   PubMed Web of Science ®Google Scholar
• BAJAJ MS, BAJAJ SP: Tissue factor pathway inhibitor: potential therapeutic applications. Thromb. Haemost. (1997) 78(0:471–477.
   PubMed Web of Science ®Google Scholar
• KOURI RK, BENES CO, INGRAM D et al.: Topical human recombinant tissue factor pathway inhibitor to pre-vent thrombosis: experimental studies and phase I trial results. Thromb. Haemost. (1997) (Suppl.):688.
   Google Scholar
• HOPPENSTEADT D, FAREED J, AMIRAL J et al.: Tissue fac-tor pathway inhibitor release is specific for heparin and low molecular weight heparins. Implications in the management of coronary syndromes. J. Am. Coll. Cardiol (1998) 31(2):53A.
   Web of Science ®Google Scholar
• RAPP JH, PAN XM, GHERMAY A et al.: A blinded trial of local recombinant tissue factor pathway inhibitor ver-sus either local or systemic heparin in a vein bypass model. J. Vasc. Surg. (1997) 25(4):726–729.
   PubMed Web of Science ®Google Scholar